Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Osteoporosis, Postmenopausal
- Type
- Observational
- Design
- Observational Model: Case-OnlyTime Perspective: Prospective
Participation Requirements
- Age
- Between 55 years and 90 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03435094
- Collaborators
- Not Provided
- Investigators
- Study Director: Aurélie TIREFORD, PharmD Labatec Pharma SA
Get Well Soon